Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Novo Nordisk (GB:0QIU)
LSE:0QIU
Holding GB:0QIU?
Track your performance easily
See the Price Targets and Ratings of:
0QIU Analyst Ratings
Moderate Buy
6 Buy
6 Hold
2 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
0QIU Stock 12 Month Forecast
Average Price Target
kr891.67
▲(22.56% Upside)
| Highest Price Targetkr1,100 | Average Price Targetkr891.67 | Lowest Price Targetkr560.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Barclays
Reiterated
11/22/24
Goldman Sachs
Reiterated
11/15/24
J.P. Morgan
Reiterated
11/11/24
Redburn Atlantic
Reiterated
11/08/24
Deutsche Bank
Reiterated
11/07/24
DZ BANK AG
Reiterated
11/07/24
Jefferies
Reiterated
11/06/24
Kepler Capital
Reiterated
11/06/24
Erste Group
Downgraded
10/28/24
Bernstein
kr560
Sell
-23.03%
Downside
Reiterated
10/21/24
Bernstein Reaffirms Their Sell Rating on Novo Nordisk (0QIU)
Bank of America Securities
kr1,150→kr1,075
Buy
47.76%
Upside
Reiterated
10/02/24
Novo Nordisk (NOVOB:DC) (NVO) PT Lowered to DKK1,075 at BofA SecuritiesBofA Securities analyst Sachin Jain lowered the price target on Novo Nordisk (NOVOB:DC) (NYSE: NVO) to DKK1,075.00 (from DKK1,150.00) while maintaining a Buy rating.
Citi
kr975
Buy
34.02%
Upside
Reiterated
09/27/24
Citi Reiterates Buy Rating on Novo Nordisk (NOVOB:DC) (NVO)Citi analyst Peter Verdult reiterated a Buy rating and DKK975.00 price target on Novo Nordisk (NOVOB:DC) (NYSE: NVO).
Berenberg Bank
kr975
Hold
34.02%
Upside
Reiterated
09/26/24
Berenberg Reiterates Hold Rating on Novo Nordisk (NOVOB:DC) (NVO)Berenberg analyst Kerry Holford reiterated a Hold rating and DKK975.00 price target on Novo Nordisk (NOVOB:DC) (NYSE: NVO).
Guggenheim
kr992→kr1,013
Buy
39.24%
Upside
Reiterated
08/19/24
Novo Nordisk price target raised to DKK 1,013 from DKK 992 at GuggenheimNovo Nordisk price target raised to DKK 1,013 from DKK 992 at Guggenheim
Best Analysts Covering Novo Nordisk
Which Analyst Should I Follow If I Want to Buy GB:0QIU and Sell After:
1 Month
xxx
Success Rate
32/51 ratings generated profit
Average Return
+1.98%
reiterated a xxx
rating 12 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 62.75% of your transactions generating a profit, with an average return of +1.98% per trade.
3 Months
xxx
Success Rate
36/51 ratings generated profit
Average Return
+7.04%
reiterated a xxx
rating 16 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 70.59% of your transactions generating a profit, with an average return of +7.04% per trade.
1 Year
Success Rate
41/51 ratings generated profit
Average Return
+29.67%
reiterated a buy rating 12 days ago
Copying Richard Vosser's trades and holding each position for 1 Year would result in 80.39% of your transactions generating a profit, with an average return of +29.67% per trade.
2 Years
xxx
Success Rate
41/51 ratings generated profit
Average Return
+41.28%
reiterated a xxx
rating 12 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 80.39% of your transactions generating a profit, with an average return of +41.28% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
0QIU Analyst Recommendation Trends
Rating
Jul 24
Aug 24
Sep 24
Oct 24
Nov 24
Strong Buy
0
0
0
0
0
Buy
28
25
26
23
23
Hold
10
7
12
15
19
Sell
3
4
4
4
3
Strong Sell
0
0
0
0
0
total
41
36
42
42
45
Each month's total comprises the sum of three months' worth of ratings.
0QIU Financial Forecast
0QIU Stock Forecast FAQ
What is GB:0QIU’s average 12-month price target, according to analysts?
Based on analyst ratings, Novo Nordisk’s 12-month average price target is kr891.67.
What is GB:0QIU’s upside potential, based on the analysts’ average price target?
Novo Nordisk has 22.56% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Novo Nordisk a Buy, Sell or Hold?
Novo Nordisk has a consensus rating of Moderate Buy, which is based on 6 buy ratings, 6 hold ratings and 2 sell ratings.
What is Novo Nordisk’s share price target?
The average share price target for Novo Nordisk is kr891.67. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is kr1,100.00 ,and the lowest forecast is kr560.00. The average share price target represents 22.56% Increase from the current price of kr727.512.
The highest analyst share price target is kr1,100.00 ,and the lowest forecast is kr560.00. The average share price target represents 22.56% Increase from the current price of kr727.512.
What do analysts say about Novo Nordisk?
Novo Nordisk’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 14 Wall Streets Analysts.
How can I buy shares of Novo Nordisk?
To buy shares of GB:0QIU, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.